Month: January 2020

Bourse Direct, leader français de la bourse sur internet, enregistre une hausse de son chiffre d’affaires de 2,9% au cours du quatrième trimestre 2019 et de 1,9% sur le second semestre 2019 comparé aux mêmes périodes en 2018. Au 31 décembre 2019, le chiffre d’affaires s’inscrit en baisse de 6,1% à31,4 millions d’euros contre 33,4 millions d’euros au 31 décembre 2018 en raison d’une activité fortement ralentie au 1ier semestre 2019Bourse Direct, leader de la bourse en ligne en France, a enregistré près de 3 millions d’ordres exécutés en 2019, en baisse de 6,4% dans un contexte de marché marqué par une contraction des volumes de capitaux traités au cours du 1ier semestre.En 2019, Bourse...

Extension of existing agreement with Roche for supply of PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®)Basel, Switzerland, January 22, 2020 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it extended its clinical supply agreement (CSA) with Roche (SIX: RO, ROG) to explore a combination of Basilea’s panFGFR kinase inhibitor derazantinib and Roche’s atezolizumab (Tecentriq®)1 in patients with gastric (stomach) cancer. The initial CSA covered urothelial (bladder) cancer and was concluded in January 2019. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study (FIDES-03) in advanced gastric cancer patients with FGFR genetic aberrations in the third quarter of 2020. The study will assess the efficacy and safety of derazantinib as mono- and combination therapy in the second-line...

Erweiterung der bestehenden Vereinbarung mit Roche zur Bereitstellung des PD-L1-Checkpoint-Inhibitors Atezolizumab (Tecentriq®)Basel, 22. Januar 2020 – Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie ihr mit Roche (SIX: RO, ROG) bestehendes Clinical Supply Agreement (CSA) erweitert hat, um die Kombination aus Basileas panFGFR-Kinase-Inhibitor Derazantinib und Roches Atezolizumab (Tecentriq®)1 bei Patienten mit Magenkrebs zu untersuchen. Die ursprüngliche Vereinbarung galt für die Indikation Urothelkarzinom (Blasenkrebs) und war im Januar 2019 abgeschlossen worden. Basilea plant, im dritten Quartal 2020 eine Biomarker-basierte Multikohorten-Phase-1/2-Studie bei Magenkrebspatienten zu starten, deren Tumore Veränderungen (Aberrationen) im FGFR-Gen aufweisen. Der Name der geplanten Studie ist...

ASML Supervisory Board changes announcedVELDHOVEN, the Netherlands, January 22, 2020 – The Supervisory Board of ASML Holding NV (ASML) today announces changes to the Supervisory Board effective from the Annual General Meeting of Shareholders (AGM) scheduled to be held on April 22, 2020.The Supervisory Board announces that Mr. W.H. (Wolfgang) Ziebart will retire at the end of his current term after having served on the board since 2009. The Supervisory Board wants to thank Mr. Ziebart for his valuable contribution over the past eleven years, during which the board has greatly benefited from his knowledge and experience. The Supervisory Board wishes him all the best for the future.The Supervisory Board intends to nominate Mr. D.W.A. (Warren) East for appointment as member of the Supervisory Board effective from the 2020 AGM. Mr. East...

ASML reports €11.8 billion sales and €2.6 billion net income in 2019Strong EUV demand and Installed Base business support expected growth in 2020ASML announces a three-year share buyback program up to €6 billion and proposes 14% annualized dividend increaseVELDHOVEN, the Netherlands, January 22, 2020 – today ASML Holding N.V. (ASML) publishes its 2019 fourth-quarter and full-year results.Q4 net sales of €4.0 billion, net income of €1.1 billion, gross margin of 48.1%Q4 net bookings of €2.4 billion2019 net sales of €11.8 billion, net income of €2.6 billionASML expects Q1 2020 net sales of between €3.1 billion and €3.3 billion and a gross margin between 46% and 47%Announces a three-year share buyback program up to €6 billion (2020-2022)Proposes a dividend over 2019 of €2.40...

PRESS RELEASE:  22 January 2020, 07:00 CETBiocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy StudyMechelen, Belgium, 22 January 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has entered into a master collaboration agreement with AstraZeneca, a global science-led biopharmaceutical company (LON/STO/NYSE: AZN). The master collaboration agreement enables the collaborative development and commercialization of Idylla™ based molecular tests in support of AstraZeneca’s pharmaceutical products.The announcement today marks a broadening of the existing partnership1 between Biocartis and AstraZeneca that focused on demonstrating how the unique...

PERSBERICHT:  22 januari 2020, 07:00 CETBiocartis gaat master samenwerkingsovereenkomst aan met AstraZeneca en start EGFR vloeibare biopsiestudieMechelen, België, 22 januari 2020 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag aan dat het een master samenwerkingsovereenkomst is aangegaan met AstraZeneca, een wetenschappelijk biofarmaceutisch bedrijf dat wereldwijd actief is (LON/STO/NYSE: AZN). Deze master samenwerkingsovereenkomst maakt de gezamenlijke ontwikkeling en commercialisatie mogelijk van op Idylla™ gebaseerde moleculaire testen ter ondersteuning van de farmaceutische producten van AstraZeneca.De aankondiging vandaag markeert een uitbreiding van de reeds bestaande...

Press release – Regulated informationPhase III study of JTA-004 in patients with knee osteoarthritis on track to start patient enrollment early 2020CTA submission initiated for Phase IIb with ALLOB in difficult tibial fracturesTwo-year follow-up Phase IIa data for ALLOB in spinal fusion expected in H2 2020Cash burn for the full year 2019 below guidanceGosselies, Belgium, 22 January 2020, 7 am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopedics and bone diseases, today provides its business outlook for 2020 and reports its cash position for the year ending December 31, 2019.Outlook for 2020Clinical Trial Application (CTA) for the knee osteoarthritis pivotal...

Communiqué de presse – Information réglementéeÉtude de Phase III évaluant JTA-004 chez des patients souffrant d’arthrose du genou prête pour recrutement des patients début 2020Soumission de la demande d’essai clinique pour la Phase IIb évaluant ALLOB chez des patients présentant des fractures difficiles du tibiaDonnées de suivi à deux ans de l’étude de Phase IIa, pour ALLOB dans la fusion vertébrale, attendues au S2 2020Consommation nette de trésorerie pour l’ensemble de l’année 2019 inférieure aux prévisionsGosselies, Belgique, 22 janvier 2020, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée...

COPENHAGEN, Denmark, January 22, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the sale of its Priority Review Voucher (PRV) has received antitrust clearance. The transaction, which was announced on December 17, 2019 will now proceed towards closing, expected by end of January 2020.For more information about the PRV sale, see company announcement no. 27/2019.About Bavarian NordicBavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains...